<DOC>
	<DOCNO>NCT02200952</DOCNO>
	<brief_summary>The purpose study prove luteal phase supplementation recombinant LH solve luteal phase deficiency Gnrh agonist oocyte trigger woman risk OHSS</brief_summary>
	<brief_title>Luteal Phase Supplementation With Recombinant LH After GnRh Agonist Oocytes Triggering Women Risk OHSS</brief_title>
	<detailed_description>The investigator enrol patient , undergo control ovarian stimulation IVF/ICSI cycle , day oocytes trigger risk OHSS . These patient estradiol &gt; 4000 pg/ml 24 follicle diameter great 12 mm . The investigator use 0,2 mg triptorelin oocytes trigger supplement luteal phase recombinant LH dose 75 UI twice/day 10 day vaginal gel progesterone oral oestradiol 14 day The investigator measure bhCG 14 day pick . In case positive bhCG define IVF/ICSI outcome : Pregnancy Rate Implantation Rate .</detailed_description>
	<mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<criteria>patient oestradiol &gt; 4000 pg/ml oocyte trigger day patient 24 follicle diameter great 12 mm oocyte trigger day patient risk OHSS oocyte trigger day patient oestradiol &lt; 4000 pg/ml oocyte trigger day patient less 24 follicle diameter great 12 mm oocyte trigger day</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>43 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>OHSS</keyword>
	<keyword>Oocytes trigger</keyword>
	<keyword>GnRh agonist trigger</keyword>
	<keyword>Luteal phase supplementation</keyword>
	<keyword>recombinant LH</keyword>
</DOC>